Omnicell Inc (OMCL)

Omnicell Inc (OMCL) shares dropped 4.2% to $33.21, placing it 12.9% below its GF Value™ of $38.15, suggesting it is undervalued. Despite a solid GF Score™ of 78/100 and favorable valuation metrics compared to historical data, insider selling of $3.2M without purchases raises caution for potential investors. Gurus, however, show a generally positive sentiment with most increasing their positions.

KeyBanc has reiterated its Overweight rating and $65.00 price target for Omnicell (NASDAQ:OMCL) after executive meetings. The firm noted that Omnicell's pipeline is the largest in years and continues to grow, with its Omnisphere product resonating well with customers. Despite recent Q2 2026 outperformance in earnings and revenue, the stock declined premarket due to concerns over softer bookings guidance and a near-term outlook, alongside reliance on a one-time tariff refund.

KeyBanc has reiterated its Overweight rating and $65.00 price target for Omnicell (NASDAQ:OMCL) after meetings with company executives, citing significant pipeline growth and the company's financial strength. Despite concerns over softer bookings guidance and a lower near-term outlook that caused a premarket stock decline following Q2 2026 results, KeyBanc believes widened bookings guidance reflects deal timing rather than weakening demand. The firm also highlighted Omnicell's strong Piotroski Score of 9 and expected net income growth, with its Omnisphere product resonating well with customers.

Trillium Asset Management LLC has acquired a new position in Omnicell, Inc. (NASDAQ:OMCL), purchasing 115,990 shares valued at approximately $4.8 million. This move is part of a broader trend where institutional investors have increased their holdings, now owning 97.7% of the company. Despite mixed analyst sentiment and a recent downgrade by Zacks, Omnicell exceeded quarterly earnings expectations, reporting $0.94 EPS against a $0.47 consensus, and maintained its 2026 full-year guidance.

Analysts have issued a "Moderate Buy" consensus recommendation for Omnicell, Inc. (NASDAQ:OMCL), with an average 12-month price target of $57.86, significantly higher than its opening price of $35.50. Despite a recent downgrade to "strong sell" by Zacks Research and some lowered price targets from other firms, Omnicell exceeded its latest quarterly earnings and revenue expectations. However, Zacks has also reduced near-term and 2027 earnings estimates, indicating a cautious outlook despite past performance.